Partner testing with HIV self-test distribution by Ugandan pregnant women living with HIV: a randomized trial.


Journal

Journal of the International AIDS Society
ISSN: 1758-2652
Titre abrégé: J Int AIDS Soc
Pays: Switzerland
ID NLM: 101478566

Informations de publication

Date de publication:
09 2023
Historique:
received: 20 10 2022
accepted: 17 08 2023
medline: 8 9 2023
pubmed: 7 9 2023
entrez: 7 9 2023
Statut: ppublish

Résumé

Secondary distribution of HIV self-tests (HIVST) by HIV-negative pregnant women to male partners increases men's testing rates. We examined whether this strategy promotes male partner testing for pregnant women living with HIV (PWLHIV). We conducted an open-label individually randomized trial in Kampala, Uganda, in which PWLHIV ≥18 years who reported a partner of unknown HIV status were randomized 2:1 to secondary distribution of HIVST for male partner(s) or standard-of-care (SOC; invitation letter to male partner for fast-track testing). Women were followed until 12 months post-partum. Male partners were offered confirmatory HIV testing and facilitated linkage to antiretroviral treatment (ART) or oral pre-exposure prophylaxis (PrEP). Using intention-to-treat analysis, primary outcomes were male partner testing at the clinic and initiation on PrEP or ART evaluated through 12 months post-partum (ClinicalTrials.gov, NCT03484533). From November 2018 to March 2020, 500 PWLHIV were enrolled with a median age of 27 years (interquartile range [IQR] 23-30); 332 were randomized to HIVST and 168 to SOC with 437 PWLHIV (87.4%) completing 12 months follow-up post-partum. Of 236 male partners who tested at the clinic and enrolled (47.2%), their median age was 31 years (IQR 27-36), 45 (88.3%) men with HIV started ART and 113 (61.1%) HIV-negative men started PrEP. There was no intervention effect on male partner testing (hazard ratio [HR] 1.04; 95% confidence interval [CI]: 0.79-1.37) or time to ART or PrEP initiation (HR 0.96; 95% CI: 0.69-1.33). Two male partners and two infants acquired HIV for an incidence of 0.99 per 100 person-years (95% CI: 0.12-3.58) and 1.46 per 100 person-years (95% CI: 0.18%-5.28%), respectively. Social harms related to study participation were experienced by six women (HIVST = 5, SOC = 1). Almost half of the partners of Ugandan PWLHIV tested for HIV with similar HIV testing rates and linkage to ART or PrEP among the secondary distribution of HIVST and SOC arms. Although half of men became aware of their HIV serostatus and linked to services, additional strategies to reach male partners of women in antenatal care are needed to increase HIV testing and linkage to services among men.

Identifiants

pubmed: 37675834
doi: 10.1002/jia2.26156
pmc: PMC10483500
doi:

Substances chimiques

Anti-Retroviral Agents 0

Banques de données

ClinicalTrials.gov
['NCT03484533']

Types de publication

Randomized Controlled Trial Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

e26156

Subventions

Organisme : NIMH NIH HHS
ID : R01MH113434
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002319
Pays : United States
Organisme : NCATS NIH HHS
ID : KL2 TR002317
Pays : United States
Organisme : NCATS NIH HHS
ID : TL1 TR002318
Pays : United States

Informations de copyright

© 2023 The Authors. Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of the International AIDS Society.

Références

Afr J AIDS Res. 2017 Jul;16(2):101-107
pubmed: 28565973
Open Forum Infect Dis. 2018 May 02;5(6):ofy097
pubmed: 29977957
J Int AIDS Soc. 2011 Apr 26;14:21
pubmed: 21521511
J Acquir Immune Defic Syndr. 2017 Oct 1;76(2):123-131
pubmed: 28737591
J Acquir Immune Defic Syndr. 2017 Mar 1;74(3):279-284
pubmed: 27828878
PLoS Med. 2016 Nov 8;13(11):e1002166
pubmed: 27824882
PLoS One. 2013;8(1):e55013
pubmed: 23383037
J Int Assoc Provid AIDS Care. 2019 Jan-Dec;18:2325958219847199
pubmed: 31104543
PLoS One. 2020 Nov 9;15(11):e0242001
pubmed: 33166351
J Acquir Immune Defic Syndr. 2019 Aug 1;81(4):379-386
pubmed: 30939530
AIDS Care. 2015;27 Suppl 1:59-64
pubmed: 26616126
Front Public Health. 2021 Feb 19;9:594298
pubmed: 33681120
PLoS One. 2019 Jul 26;14(7):e0219967
pubmed: 31348782
Int J Surg. 2011;9(8):672-7
pubmed: 22019563
EClinicalMedicine. 2021 Jul 07;38:100991
pubmed: 34278282
Afr J Lab Med. 2016 Oct 17;5(2):447
pubmed: 28879125
Lancet Glob Health. 2021 Jul;9(7):e977-e988
pubmed: 34143996
Lancet Glob Health. 2021 Dec;9(12):e1719-e1729
pubmed: 34735862
SAHARA J. 2015;12:87-105
pubmed: 26726756
BMC Public Health. 2022 Nov 24;22(1):2170
pubmed: 36434555
Syst Rev. 2013 Jan 16;2:5
pubmed: 23320454
J Acquir Immune Defic Syndr. 2020 Jul 1;84(3):271-279
pubmed: 32168168

Auteurs

Andrew Mujugira (A)

Infectious Diseases Institute, Makerere University, Kampala, Uganda.

Agnes Nakyanzi (A)

Infectious Diseases Institute, Makerere University, Kampala, Uganda.

Deborah Donnell (D)

Fred Hutch Cancer Center, Seattle, USA.

Jade Boyer (J)

Department of Global Health, University of Washington, Seattle, Washington, USA.

Gabrielle Stein (G)

Department of Global Health, University of Washington, Seattle, Washington, USA.

Michelle Bulterys (M)

Department of Epidemiology, University of Washington, Seattle, Washington, USA.

Faith Naddunga (F)

Infectious Diseases Institute, Makerere University, Kampala, Uganda.

Juliet Kyomugisha (J)

Infectious Diseases Institute, Makerere University, Kampala, Uganda.

Juliet E Birungi (JE)

Infectious Diseases Institute, Makerere University, Kampala, Uganda.

Paul Ssendiwala (P)

Infectious Diseases Institute, Makerere University, Kampala, Uganda.

Rogers Nsubuga (R)

Infectious Diseases Institute, Makerere University, Kampala, Uganda.

Timothy R Muwonge (TR)

Infectious Diseases Institute, Makerere University, Kampala, Uganda.

Joshua Musinguzi (J)

AIDS Control Program, Ministry of Health, Kampala, Uganda.

Monisha Sharma (M)

Department of Global Health, University of Washington, Seattle, Washington, USA.

Connie L Celum (CL)

Departments of Global Health, Medicine, and Epidemiology, University of Washington, Seattle, Washington, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH